CCDC 1043880: Experimental Crystal Structure Determination
Christopher R. Butler(Pfizer (United States)), Brian T. O’Neill(Pfizer (United States)), Cathleen Gonzales, David Riddell(Eli Lilly (United States)), Kevin Parris, Luis Martinez-Alsina(Pfizer (United States)), Christopher J. Helal(Pfizer (United States)), Leanne M. Buzon(Pfizer (United States)), Kevin Ogilvie(Pfizer (United States)), Charles E. Nolan(Pfizer (United States)), Shawn D. Doran(Pfizer (United States)), Kevin Atchison(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ashley Robshaw(Pfizer (United States)), F.F. Vajdos(University of Utah), Gabriela Barreiro(Pfizer (United States)), Elizabeth M. Beck(Pfizer (United States)), Michael A. Brodney(Vertex Pharmaceuticals (United States))
Cited by 0
Related Papers
ApoE Promotes the Proteolytic Degradation of Aβ
|Neuron|2008|869
Application of the Bicyclo[1.1.1]pentane Motif as a Nonclassical Phenyl Ring Bioisostere in the Design of a Potent and Orally Active γ-Secretase Inhibitor
|Journal of Medicinal Chemistry|2012|460
Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease
|Nature Medicine|2020|445
Impact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels
|Journal of Neuroscience|2008|351